Bayer stock in green: Bayer applies for extended approval for cancer drug Nubeqa in the US and the EU

Extended indications for a combination therapy with the Nubeqa active ingredient darolutamide for the treatment of metastatic hormone-sensitive prostate cancer have been requested from the US health authority FDA and the European Medicines Agency EMA, as the pharmaceutical and agrochemical group announced in Berlin.

A recent study of 1,300 men suffering from this type of prostate cancer found that Nubeqa combined with chemotherapy and hormone therapy reduced their risk of death by a third compared to standard therapy alone.

Nubeqa is considered one of the hopes among Bayer’s new drugs. So far it has been approved for the treatment of non-metastatic castration-resistant prostate cancer. In light of the latest study results, Bayer recently increased the peak sales potential for Nubeqa from more than €1 billion to more than €3 billion.

Darolutamide is being developed jointly by Bayer and the Finnish pharmaceutical company Orion. Further approval applications are planned. The active ingredient is also being investigated in further studies in various stages of prostate cancer.

Bayer shares temporarily gained 5.17 percent on XETRA to EUR 53.12.

FRANKFURT (Dow Jones)

Image sources: Lukassek / Shutterstock.com, Arseniy Krasnevsky / Shutterstock